Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine how well the combination of bevacizumab
and carboplatin works in treating breast cancer that has spread to the brain. Bevacizumab is
an antibody (a protein that attacks a foreign substance in the body) that is made in the
laboratory. Bevacizumab works differently from the way chemotherapy drugs work. Usually
chemotherapy drugs attack fast growing cancer cells in the body. Bevacizumab works to slow or
stop the growth of cells in cancer tumors by decreasing the blood supply to the tumors. When
the blood supply is decreased, the tumors don't get the oxygen and nutrients they need to
grow. Carboplatin is in a class of drugs known as platinum-containing compounds and has been
approved for use in the treatment of ovarian cancer. Information from other research studies
suggests that the combination of bevacizumab with carboplatin may be effective in treating
breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Genentech, Inc. Massachusetts General Hospital